Risk stratification by somatic mutation burden in Ewing sarcoma

Up to one‐third of patients with localized Ewing sarcoma (ES) develop recurrent disease, but current biomarkers do not accurately identify this high‐risk group. Therefore, the objective of this study was to determine the utility of mutational burden in predicting outcomes in patients with localized ES.

[1]  M. Mann,et al.  A review of soft-tissue sarcomas: translation of biological advances into treatment measures , 2018, Cancer management and research.

[2]  D. Compton,et al.  STAG2 promotes error correction in mitosis by regulating kinetochore–microtubule attachments , 2014, Journal of Cell Science.

[3]  W. Winkelmann,et al.  Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  U. Moll,et al.  Links between mutant p53 and genomic instability , 2012, Journal of cellular biochemistry.

[5]  A. Craft,et al.  Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Beauchamp.  Ewing Sarcoma Demonstrates Racial Disparities in Incidence-related and Sex-related Differences in Outcome: An Analysis of 1631 Cases From the SEER Database, 1973-2005 , 2010 .

[7]  A. McKenna,et al.  The genomic landscape of pediatric Ewing sarcoma. , 2014, Cancer discovery.

[8]  Shamil R. Sunyaev,et al.  Impact of deleterious passenger mutations on cancer progression , 2012, Proceedings of the National Academy of Sciences.

[9]  K. Cole,et al.  Comprehensive Analysis of Hypermutation in Human Cancer , 2017, Cell.

[10]  T. Halazonetis,et al.  Genomic instability — an evolving hallmark of cancer , 2010, Nature Reviews Molecular Cell Biology.

[11]  Nikhil Wagle,et al.  High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. , 2012, Cancer discovery.

[12]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[13]  A. Niemierko,et al.  Clinical Impact of Tumor Mutational Burden in Neuroblastoma. , 2018, Journal of the National Cancer Institute.

[14]  S. Ferrari,et al.  Prognostic factors in non-metastatic Ewing's sarcoma tumor of bone: An analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998 , 2006, Acta oncologica.

[15]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[16]  I. Judson,et al.  How to treat the Ewing's family of sarcomas in adult patients. , 2006, The oncologist.

[17]  L. Koniaris,et al.  Ewing sarcoma demonstrates racial disparities in incidence‐related and sex‐related differences in outcome , 2009, Cancer.

[18]  U. Dirksen,et al.  Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Healey,et al.  Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Gerald,et al.  EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Jun S. Wei,et al.  The Genomic Landscape of the Ewing Sarcoma Family of Tumors Reveals Recurrent STAG2 Mutation , 2014, PLoS genetics.

[22]  M. Ladanyi,et al.  Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[24]  Yubo Gao,et al.  Prognostic factors for survival in patients with Ewing's sarcoma using the surveillance, epidemiology, and end results (SEER) program database. , 2015, Cancer epidemiology.

[25]  Li Ding,et al.  Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. , 2014, Cancer discovery.

[26]  A. Llombart‐Bosch,et al.  Molecular Analysis of the 9p21 Locus and p53 Genes in Ewing Family Tumors , 2001, Laboratory Investigation.